Posted by Michael Wonder on 02 Oct 2024
Clinuvel files Canadian new drug submission for Scenesse in EPP
30 September 2024 - Patient special access program continues during Health Canada review.
Clinuvel has filed a new drug submission to Health Canada, seeking approval for its novel photoprotective therapy Scenesse (afamelanotide) for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria.
